Topical bromfenac reduces the frequency of intravitreal bevacizumab in patients with branch retinal vein occlusion.
A study from Japan evaluated the effectiveness of topical bromfenac during treatment with intravitreal injections of bevacizumab (IVB) in eyes with macular oedema (ME) secondary to branch retinal vein occlusion (BRVO). This prospective interventional case–control study included 48 eyes of 44 patients with ME-BRVO. The patients, given 1.25 mg/0.05 mL of IVB, showed temporary regression of ME. Additional IVB were given when ME recurred. 24 eyes received topical bromfenac, and the other 24 eyes received topical saline as control, four times a day during the clinical course of 48 weeks.
The clinical course of foveal thickness (FT) as measured by optical coherence tomography and logarithm of the minimum angle of resolution visual acuity (VA), was monitored. The number of IVB was also recorded.
There were no significant differences in FT, VA between the bromfenac-treated eyes and the control eyes at the initial and final examinations. The number of injections in bromfenac-treated eyes of 3.8±1.1 times was significantly less than in the control eyes of 4.8±1.2 times.
The study concludes that although topical bromfenac during IVB therapy in eyes with ME secondary to BRVO did not affect the visual prognosis, it had the advantage of reducing the number of injections.